Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 + camrelizumab + apatinib in advanced hepatocellular carcinoma after immune checkpoint inhibitor failure
CTR20261606Phase 2Active
- Sponsor
- Virotech Pharmaceutical
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VRT-106, camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Virotech Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
VRT-106camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20261606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261606.